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Background: This study was designed to evaluate the protective effects of thalidomide on paraquat (PQ)-induced
lung injuries in a rat model and to explore the underlying mechanisms.
Methods: Rats were exposed to 50 mg/kg PQ by oral gavage, and treated with thalidomide through oral
administration at 60 mg/kg once a day, 6 days/week for 2 weeks. Serum levels of IL-6, TNF-alpha, TGFbeta1 and
COL1A1 were detected at different time points after paraquat exposure. At the end of the study, lung tissues were
collected for pathological inspection as well as analyses of water content and expression levels of IL-6, TNF-alpha,
TGFbeta1 and COL1A1 mRNA.
Results: The results showed that thalidomide treatment could significantly alleviate PQ-induced pathological
changes in lung tissue and severity of lung edema. Thalidomide treatment after PQ exposure resulted in significantly
reduced serum levels of IL-6, TNF-alpha, TGF-beta1 and COL1A1, as compared to PQ group. PCR analysis demonstrated
that expression levels of IL-6, TNF-alpha, TGF-beta1 and COL1A1 in lung tissue were significantly increased after PQ
exposure but reduced by thalidomide, which were confirmed by immunohistochemistry staining.
Conclusions: Our results indicated that inflammatory factors played important roles in PQ-induced lung injuries and
thalidomide could protect rats from PQ-induced lung injuries by inhibiting the upregulation of inflammatory factors.
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Paraquat (1,1′-dimethyl-4,4′-bipyridilium dichloride, PQ)
is a widely used nonselective herbicide around the world
and the incidence rate of PQ intoxication has been re-
ported to be increasing. The primary damages caused by
PQ occur in lung tissue due to the accumulation of PQ.
PQ exposure results in acute damage and destruction of
alveolar epithelial cells, pulmonary edema, and infiltration
of inflammatory cells within a few days. The acute injury
phase is then followed by a final pulmonary fibrotic phase
that lasts for several weeks featured by infiltration of myo-
fibroblasts into the alveolar spaces and septa, and differen-
tiation in fibroblasts with the production of collagen [1].* Correspondence: 1183969122@qq.com
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creativecommons.org/publicdomain/zero/1.0/Pulmonary fibrosis is a major hallmark and a leading
cause of death in PQ intoxication. The high mortality rate
of PQ-intoxicated patients imposes a challenge to clinical
practitioners due to the lack of an antidote or effective
treatment to prevent pulmonary fibrosis [2].
A number of studies have suggested that the PQ-
induced oxidative stress is the primary mechanism for
initiating lung damage by PQ. PQ intoxication generates
numerous oxygen free radical species by cyclic oxido-
reduction of PQ, which cause disruptions of alveolar epi-
thelial cells and Clara cells, infiltration of inflammatory
cells into the interstitial and alveolar spaces, upregula-
tion of several genes involved in inflammatory response,
proliferation of fibroblasts, and deposition of excessive
collagen [1, 3]. Several inflammatory cytokines, particu-
larly TNF-α, IL-6, IL-1β, and TGF-β1 are found to play
key roles in the pathogenesis of PQ-induced lung injurydistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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for PQ poisoning, anti-inflammatory drugs including
corticosteroids and immunosuppressive drugs have been
used in the clinical treatment for PQ intoxication [6, 7].
Thalidomide (Thal), originally developed in the 1950s
as a tranquilizer, was discontinued for its potent terato-
genic effects in the 1960s. It has recently being shown to
have various pharmacological properties, including
immunomodulation [8], anti-inflammation [9–11], and
anti-angiogenesis [12]. Thalidomide and its analogs have
been used in the treatment of a variety of disorders in-
cluding erythema nodosum leprosum, multiple mye-
loma, rheumatoid arthritis, Crohn’s disease, prostate
cancer and lupus erythematosus [13]. In recent experi-
mental studies, thalidomide has been demonstrated to
have anti-fibrotic effects by suppressing the expression
of IL-6, TGF-β, and angiogenesis-related growth factors
that play a crucial role in the proliferation and differenti-
ation of lung fibroblasts [14].
Based on the fact that inflammatory mediators con-
tribute greatly to PQ-induced acute lung injury and sub-
sequent fibrosis, we hypothesize that thalidomide may
be potentially used to relieve PQ-induced pulmonary
inflammation and fibrosis. In the present study, we
explored whether Thal has protective effects on PQ-
induced lung injury and fibrosis using PQ intoxication
rat model. Moreover, we also investigated the mecha-
nisms underlying the therapeutic effect of thalidomide
on pulmonary inflammation and fibrosis.
Methods
Reagents
Paraquat was provided by Shandong Yinuo Company
(Shandong, China); Thalidomide was purchased from
Changzhou Pharmaceutical Company (Changzhou, China);
Polyclonal antibodies against TNF-α, IL-6, TGFβ1 and
collagen-1 were purchased from Boster Biological
Technology (Wuhan, China); Horseradish peroxidase
(HRP)-conjugated goat anti-rabbit secondary antibody
and streptavidin-peroxidase immunohistochemistry kit
were provided by Beijing Zhongshan-Golden Bridge
Biological Technology (Beijing, China); Trizol and
SuperScript II Reverse Transcriptase were obtained
from Invitrogen (Carlsbad, USA); Taq DNA polymerase
and DNA size marker were purchased from Beijing
Dingguo Changsheng Biotechnology (Beijing, China).
Animal model and experimental procedures
All animal studies were performed in accordance with the
guidelines of the Jilin University and the animals received
human care in compliance with the Principles of Labora-
tory Animal Care. Healthy female Wistar rats weighing
250 ~ 300 g purchased from Animal Research Center of
Jilin University were hosted in a pathogen-free animalfacility under a standard 12-h light/12-h dark cycle. Rats
were fed standard rodent chow and water ad libitum.
Rats were randomly assigned to three groups: (1) nor-
mal control group, five rats with oral administration of
1 ml of 0.9 % NaCl solution only; (2) PQ group, 14 rats
with one time oral administration of paraquat (50 mg/kg)
in 1 ml of saline; and (3) PQ+ Thal group, ten rats with
one time oral administration of paraquat (50 mg/kg) in
1 ml of saline followed by oral gavage of thalidomide at
60 mg/kg once a day, 6 days/week for 2 weeks. Blood sam-
ples were collected through retro-orbital bleeding at days
1, 2, 3, 5, 7, 10 and 15 after paraquat exposure for detec-
tion of IL-6, TNF-α, TGFβ1 and COL1A1 levels. Rats were
euthanized at day 15 and lung tissues were collected for
analyses of water content and expression levels of IL-6,
TNF-α and COL1A1 mRNA in lung as well as patho-
logical inspection.
Detection of serum IL-6, TNF-α, TGFβ1 and COL1A1 levels
The concentrations of IL-6, TNF-α, TGFβ1 and COL1A1
were determined using ELISA. Briefly, 96-well, flat bot-
tom plates were coated with serum samples overnight at
4 °C. The plates were washed and blocked with PBS with
10 % fetal bovine serum for 1.5 h. After the plates were
washed, primary detection antibodies specific to IL-6,
TNF-α, TGFβ1 and COL1A1 were added to the respec-
tive wells for 1.5 h. The plates were washed and horse-
radish peroxidase (HRP)-conjugated secondary antibody
was added to the plates for 1.5 h. Following a series of
stringent washing, the substrate reagent was added into
each well and absorbance was read at 490 nm using the
plate reader. The detection limits of ELISA methods for
IL-6, TNF-α, TGFβ1 and COL1A1 were all below 50 pg/ml.
Histological examinations of the lungs
The lung tissues from each treatment group were excised,
fixed in 10 % buffered formalin and then embedded in
paraffin. Sliced lung tissue sections (2 μm in thickness)
were stained with Hematoxylin-and-Eosin (H&E) and
pathological changes were examined by experienced pa-
thologists. Masson’s trichrome staining was used to assess
collagen deposition in lung extracellular matrix.
Detection of mRNA expression levels of IL-6, TNF-α,
TGFβ1 and COL1A1 in the lungs by Reverse
Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA from rat lung tissue was extracted using
Trizol (Invitrogen, California, USA) by following manu-
facturer’s instruction. cDNA was synthesized from 2 μg
of total RNA by using SuperScript II reverse transcrip-
tion kit (Invitrogen, California, USA) for each sample.
Conventional PCR was used to detect expression levels
of IL-6, TNF-α, TGFβ1 and COL1A1 with GAPDH used
as endogenous control. The specific primer sets (Table 1)
Table 1 Primers used for the PCR detection of specific gene expression
Gene Forward Reverse PCR product size
TGF-β1 5′-GACTCCTGCTGCTTT CTCC-3′ 5′-GCGGTCCACCATTA GCAC-3′ 531 bp
IL-6 5′-CCACGGCCTTCCCTA CTTC-3′ 5′-TTGGTCCTTAGCCAC TCCT-3′ 499 bp
COL1A1 5′-GTCCTATGGCTATGATG AGAA ATC-3′ 5′-CACCATCCAAACCA CTGAAAC-3′ 335 bp
TNF-a 5′-GTCCCCAAAGGGATGA GAAG T-3′ 5′-TGAGATAGCCAAATCG GCT GAC-3′ 323 bp
GAPDH 5′-ACCACAGTCCATGCCAT CAC-3′ 5′-TCCACCACCCTGTTGCT GTA-3′ 452 bp
Table 2 Water content of lung tissues at the end of experiment
Group Lung water content
Normal control 4.94 ± 0.24
PQ 5.21 ± 0.72
PQ + Thal 4.63 ± 0.54*
Data are presented as (Mean ± SD)
*P < 0.05, compared to PQ
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NCBI GenBank database. The thermal cycling condi-
tions included 1 cycle at 94 °C for 2 min and 35 cycles
at 94 °C for 1 min, 50 °C for 1 min and 72 °C for 1 min
followed by 1 cycle at 72 °C for 10 min. PCR products
were resolved by electrophoresis on 1.5 % agarose gel
and images were collected using gel imaging system.
Immunohistochemistry detection of IL-6, TNF-α, TGFβ1
and COL1A1 expression in the lungs
Immunohistochemical staining (IHC) was performed
using streptavidin-peroxidase immunohistochemistry kit
by following the instructions. Rabbit polyclonal anti-
bodies against TNF-α, IL-6, TGFβ1 and COL1A1 were
used as primary antibodies, and equal amount of puri-
fied rabbit IgG was used as negative control. The signal
was developed using DAB substrate.
Statistical analysis
All data were presented as the mean ± standard differ-
ences (S.D.). Data were analyzed by one-way analysis of
variance (ANOVA) with Bonferroni post-tests for com-
parison between groups. In all cases, the difference was
considered statistically significant as P < 0.05.
Results
Effects of thalidomide on PQ-induced morbidity and
mortality
The rats in PQ group presented with tachypnea, labored
breathing, and anorexia within 2 to 3 days post PQ ex-
posure. Two out of 14 rats died on day 2 and one died
on day 3 after PQ administration. Severe interstitial
edema, alveolar hemorrhage, and inflammation in all al-
veolar interstitial tissues and lumens were observed at
necropsy (data not shown). In contrast, no apparent signs
of respiratory distress were observed in rats in PQ + Thal
group after PQ exposure and no animal died in this
group.
Effect of thalidomide on lung water content
Lung water content was calculated by the formula of
(lung wet weight-lung dry weight)/lung dry weight. Lung
water content was higher in PQ group at day 15 post
PQ exposure compared to control group and wassignificantly reduced in the PQ + Thal group compared
to PQ group (p < 0.05) (Table 2). This indicated that lung
edema remained for a long period of time following PQ
intoxication, and treatment with thalidomide could ef-
fectively relieve PQ-induced lung edema.
Thalidomide alleviated the histopathological changes of
lung caused by PQ
PQ-induced lung structural changes and alleviative effects
of thalidomide on PQ-induced damages are depicted in
Fig. 1. Histological changes were assessed with H&E
staining and lung fibrosis was identified by using Masson’s
Trichrome stain for collagen. Animals from control group
presented a normal pulmonary structure at light micros-
copy, without evidences of alveolar collapse, cellular infil-
trations, or collagen accumulation. Paraquat intoxicated
rat lung on day 15 showed diffuse alveolar damages with
thickening of alveolar walls and widespread inflammation
in alveolar spaces and septa. There were significant
peribronchial and perialveolar deposition of collagen
observed in Masson’s trichrome staining. In comparison
with the PQ group, the occurrence of the above, referred
alterations were drastically attenuated in the PQ +Thal
groups, particularly inflammation, hemorrhage, and the
amount of accumulation of collagenous fiber.
Effects of thalidomide on serum levels of IL-6, TNF-α,
TGF-β1 and COL1A1 induced by PQ
Serum levels of IL-6, TNF-α, TGF-β1 and COL1A1 were
measured by ELISA on day 1, 3, 5, 7, 10 and 15 after PQ
exposure. In PQ group, serum IL-6 levels significantly
elevated on day 1 compared to control group, peaked on
day 3, and gradually reduced thereafter. Thalidomide
treatment resulted in accelerated reduction of PQ-










Fig. 1 Thalidomide alleviated PQ induced histopathological changes in lung tissues in rats. Lung tissues from Control (a, b), PQ (c, d) and PQ+ Thal
(e, f) groups were subjected to pathological examination on day 15 after PQ administration by hematoxylin and eosin staining (×100) (a, c, e) and









































































































Fig. 2 Effects of thalidomide on serum levels of IL-6, TNF-α, TGF-β1 and COL1A1 induced by PQ. Blood samples from rats from each treatment
group were collected through retro-orbital bleeding at days 1, 2, 3, 5, 7, 10 and 15 after paraquat exposure and serum levels of IL-6 (a), TNF-α (b),
TGF-β1 (c) and COL1A1 (d) were measured by ELISA. The values represent mean ± SD from each group (● Control, ■ PQ group and▲ PQ+ Thal
group). * p <0.05 compared to Control, # p <0.05 compared to Paraquat
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post PQ exposure, peaked on day 3, and remained
higher than control group on day 5. Rats treated with
thalidomide following PQ exposure had significantly re-
duced serum TNF-α levels on day 3 and 5 compared to
PQ group (Fig. 2b).
PQ caused serum levels of TGF-β1 to increase on day
5 and peak on day 7 after oral ingestion. However, no
significant changes of serum TGF-β1 levels were ob-
served in rats treated with thalidomide after PQ expos-
ure (Fig. 2c).
Serum COL1A1 levels in rats of PQ group significantly
elevated on day 3, peaked on day 7 and remained higher
than control on day 15. Thalidomide treatment com-
pletely reversed the PQ-induced increase of COL1A1
levels (Fig. 2d).
Effects of thalidomide on mRNA expression levels of IL-6,
TNF-α, TGF-β1 and COL1A1 in lung tissues after PQ
intoxication
Expression levels of IL-6, TNF-α, TGF-β1 and COL1A1
mRNA transcripts in lung tissues were examined using
RT-PCR on day 15 after PQ administration (Fig. 3). Ex-
pressions of IL-6 and TNF-α mRNA were significantly
up-regulated in lung tissues in PQ group compared to
control, indicating the involvement of inflammatory cy-
tokines in PQ-induced pathological changes of lung. In
addition, expressions of TGF-β1 and COL1A1, two im-
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Fig. 3 Effects of thalidomide on expression levels of IL-6, TNF-α, TGF-β1 an
treatment group were excised on day 15 after PQ administration and mRN
examined using RT-PCRat mRNA level in lung tissues at 15 days after PQ expos-
ure. However, expressions of IL-6, TNF-α, TGF-β1 and
COL1A1 transcripts were all significantly lower in lung
tissues from rats treated with thalidomide after PQ ex-
posure compared to PQ group. These results indicate
that thalidomide may prevent PQ-induced pulmonary fi-
brosis through downregulating the expression of TGF-β
1, TNF-α and IL-6 in lung tissues.
Immunohistochemistry detection of the expression of
IL-6, TNF-α, TGF-β1 and COL1A1 proteins in lung tissues
after PQ intoxication
Expression of IL-6, TNF-α, TGF-β1 and COL1A1 pro-
teins in lung tissues were examined using immunohisto-
chemical staining on day 15 after PQ administration. As
shown in Fig. 4, there were weak and diffused signals of
IL-6 and TNF-α on vascular walls and alveolar walls in
normal lung tissues from control group. Enhanced sig-
nals of IL-6 and TNF-α stainings were observed on
alveolar walls in lung tissues from PQ group on day 15
post PQ exposure and thalidomide treatment signifi-
cantly reduced IL-6 and TNF-α expression in lung tis-
sues. Expression of TGF-β1, which was detected at low
levels on alveolar walls in normal lung tissues, was in-
creased in lung tissues from PQ group and significantly
reduced by thalidomide treatment (Fig. 4). In normal
lung tissues, COL1A1 is mainly detected on vascular
walls and weakly expressed on alveolar walls. Although
expression of COL1A1 in alveolar walls was dramaticallyp
bp
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Fig. 4 Immunohistochemistry detection of the expression of IL-6, TNF-α, TGF-β1 and COL1A1 proteins in lung tissues after PQ intoxication. Lung
tissues from Control (a, d, g, j), PQ (b, e, h, k) and PQ + Thal (c, f, i, l) groups were collected on day 15 after PQ administration and expression of
IL-6 (a, b, c), TNF-α (d, e, f), TGF-β1 (g, h, i) and COL1A1 (j, k, l) in lung tissues were examined using immunohistochemical staining (×100)
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sulted in significantly decreased COL1A1 expression in
lung tissues compared to PQ group.
Discussion
Intoxication of paraquat, a highly toxic quaternary am-
monium herbicide, has a high mortality rate and poor
prognosis due to severe acute lung injury and subse-
quent pulmonary fibrosis [15]. In this study we have
demonstrated that thalidomide has a protective effect
against PQ-induced lung injury and pulmonary fibrosis
in rats. Our results showed that administration of thalido-
mide at 60 mg/kg could significantly reduce the degree of
lung edema and pulmonary fibrosis caused by PQ in rats.
Moreover, our data also suggested that the protective ef-
fect of thalidomide against PQ-induced pulmonary fibrosis
was associated with decreased expression levels ofinflammatory factors such as TGF-β1, TNF-α and IL-6 in
lung tissues after PQ exposure.
Lung is one of the major organs affected by PQ during
PQ intoxication due to the accumulation of PQ in the
lung through the active polyamine uptake system in the
membrane of alveolar cell [1, 3]. Although the molecular
mechanism of PQ-induced lung injuries is not fully
understood, oxidative and inflammatory mediators have
been found to play important roles in this process. It has
become increasingly clear that reactive oxygen species
generated through the cyclic oxido-reduction of PQ can
not only result in tissue damages directly but also initiate
and promote inflammatory responses through upregula-
tion of inflammatory cytokines and adhesion molecules
[16–18]. Such inflammatory cytokines, particularly IL-6,
TNF-α, TGF-β1 are found to be involved in the patho-
genesis of PQ-induced pulmonary inflammation and
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kines that are released in both early acute inflammatory
and late fibrotic phases of PQ-induced lung injury [4].
TGF-β1 as the most important fibrogenic growth factor
has been shown to stimulate fibroblast proliferation,
matrix protein production and collagen synthesis [21]. In-
creased production of TGF-β1 from lung injury caused by
PQ has been associated with inflammation and fibrosis of
lung tissue [19, 20]. In this study, we observed that the
serum levels of IL-6 and TNF-α quickly elevated on day 1,
peaked on day 3 and remained higher than control on day
5 after PQ exposure in rats. However, serum TGF-β1 level
was not increased until day 5 and peaked on day 7 after
PQ exposure. In addition, immunohistochemistry detec-
tion for the expression of IL-6, TNF-α and TGF-β1 in lung
tissues from rats on day 15 after PQ intoxication showed
significant overexpression of these factors in lung tissues
compared to control normal lung tissues. Our results, con-
sistent with other studies [4, 19, 20], demonstrate that in-
flammatory factors play important roles in PQ-induced
lung injuries with proinflammatory factors IL-6 and TNF-α
involved in both acute and chronic phases and TGF-β1
mainly in late fibrotic phase of PQ-induced lung injury.
Thalidomide and its analogs have been used in clinic
as immunomodulatory drugs with anti-inflammatory,
anti-proliferative and anti-angiogenic activities. It has
been shown that thalidomide exhibits anti-inflammatory
and anti-fibrotic activities by suppressing the production
of proinflammatory cytokines and growth factors that
play important roles in the tissue destruction and fibrosis
in chronic inflammatory situations [19, 22, 23]. Several
studies using animal models have demonstrated that thal-
idomide has therapeutic effects for fibrotic and inflamma-
tory disorders such as bleomycin-induced lung fibrosis
[14], peritonitis [23], pancreatitis [24], experimental dia-
betes [22] and liver cirrhosis [25]. Moreover, thalidomide
was recently shown to protect against PQ-induced lung
injury through different mechanisms in PQ-intoxication
mouse models [26–28]. Amirshahrokhi [26] showed that
6 days treatment of thalidomide in PQ intoxicated mice
resulted in decreased production of inflammatory and
fibrogenic cytokines including TNF-α, IL-1β, IL-6, and
TGF-β1 as well as reduced myeloperoxidase (MPO), nitric
oxide (NO), and hydroxyproline content in lung tissues.
In another two published studies performed by a Chinese
group [27, 28], thalidomide was shown to attenuate PQ-
induced acute lung injury through multiple mechanisms
which involved downregulation of TNF-α, IL-1β, and IL-6
via inhibition of NF-κB activation as well as protection
from PQ-induced lipid peroxide damage by activation of
the Nrf2-ARE signaling pathway. In the current study we
employed a 15-day thalidomide treatment regimen in the
PQ intoxication rat model to evaluate the effects and po-
tential mechanisms of thalidomide on PQ-induced lunginjury, especially pulmonary fibrosis subsequent to
acute lung injury phase. Our results showed that thal-
idomide treatment after PQ administration resulted in
improved survival and rats treated with thalidomide
had significantly reduced lung edema and improved
pulmonary function at 15 days after treatment. Histo-
logical analysis showed that PQ-induced lung injuries
characterized by a marked thickening of the alveolar
septum and infiltration of various inflammatory cells
were attenuated by administration of thalidomide. Lung
fibrosis and collagen deposition caused by PQ was sig-
nificantly relieved after 15-day thalidomide treatment
as indicated by Masson’s Trichrome staining. To ex-
plore the mechanisms of the protective effect of thal-
idomide on PQ-induced lung injury, we examined the
expression levels of several inflammatory factors in-
cluding TNF-α, IL-6 and TGF-β1 that play important
roles in pathogenesis of PQ-induced lung damages in
both blood and lung tissues. Our results showed that
blood levels of TNF-α and IL-6 elevated to lower levels
and reduced to normal in a shorter time after PQ ex-
posure in rats treated with thalidomide as compared to
control PQ intoxicated rats without thalidomide treat-
ment. TGF-β1 as one of the major fibrogenic factors in
PQ-induced pulmonary fibrosis was significantly upreg-
ulated in blood at day 5 after PQ exposure, while thal-
idomide treatment completely reversed PQ-induced
increase of TGF-β1 level in blood. Similarly, increase of
blood COL1A1 level due to PQ exposure was also cor-
rected by thalidomide treatment. These results indi-
cated that immediate treatment with thalidomide after
PQ intoxication could interfere with the onset of in-
flammatory and fibrogenic process and therefore sig-
nificantly ameliorate pulmonary fibrosis. In addition,
immunohistochemistry staining and PCR detection for
expression of TNF-α, IL-6 and TGF-β1 in lung tissues
on day 15 after PQ intoxication further confirmed that
thalidomide could significantly reduce the upregulation
of the expression of these factors induced by PQ at
both protein and RNA levels. Our findings together
with others [26–28] indicate that thalidomide may exhibit
anti-inflammatory and anti-fibrosis effects in a non-
specific way by regulating the expression of several key in-
flammatory factors, such as TNF-α, IL-6 and TGF-β1.
However, more sophisticated studies are needed to further
identify potential signaling pathways and molecular me-
chanisms of thalidomide’s anti-inflammatory and anti-
fibrosis effects against PQ-induced lung injury.
Conclusions
Thalidomide exhibits protective effect against PQ-
induced acute lung injury and subsequent fibrosis by
inhibiting the upregulation of inflammatory factors, par-
ticularly IL-6, TNF-α and TGF-β1 in lung. Since PQ-
Li et al. Journal of Inflammation  (2015) 12:46 Page 8 of 8induced lung damage begins at a very early stage of PQ
poisoning, the treatment with thalidomide should be ap-
plied as early as possible after PQ exposure. Our results
support clinic trials to explore whether adding thalido-
mide to current treatment regimen can improve the out-
comes of patients with PQ intoxication.
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